

Jan Tesarik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9405305/publications.pdf>

Version: 2024-02-01

45
papers

1,584
citations

643344

15
h-index

340414

39
g-index

47
all docs

47
docs citations

47
times ranked

1106
citing authors

#	ARTICLE	IF	CITATIONS
1	Virtual sonographic hysteroscopy in assisted reproduction: A retrospective cost-effectiveness analysis. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 156, 112-118.	1.0	13
2	Double HCG trigger improves recovery of oocytes in women with a paucifollicular response to ovarian stimulation: A pilot study. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 157, 149-153.	1.0	2
3	Impaired fertility after unilateral oophorectomy: what's the cause and what can be done?. <i>Fertility and Sterility</i> , 2022, , .	0.5	0
4	Use of pentoxifylline during ovarian stimulation to improve oocyte and embryo quality: A retrospective study.. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102398.	0.6	3
5	Endometrial scratching: less invasive methods should be tried first. <i>Reproductive BioMedicine Online</i> , 2022, 45, 417.	1.1	1
6	Individually started versus randomly started mild ovarian stimulation for IVF in poor responders. <i>Reproductive BioMedicine Online</i> , 2021, 42, 285.	1.1	2
7	Effect of growth hormone administration on ICSI outcomes in patients with polycystic ovary syndrome and recurrent implantation failure: A retrospective cross-over study. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 357-358.	1.0	4
8	Fertility Preservation in the Time of COVID-19. <i>Journal of Fertility Preservation</i> , 2021, 2, 1-4.	0.2	0
9	Editorial: Growth Hormone in Fertility and Infertility: Physiology, Pathology, Diagnosis and Treatment. <i>Frontiers in Endocrinology</i> , 2021, 12, 621722.	1.5	5
10	Ovarian Aging: Molecular Mechanisms and Medical Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1371.	1.8	37
11	Novel diagnostic approaches to intrauterine neoplasm in fertile age: sonography and hysteroscopy. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2021, 30, 288-295.	0.6	5
12	Rationale for the continued use of melatonin to combat the delta variant of SARS-CoV-2. <i>Melatonin Research</i> , 2021, 4, 495-500.	0.7	3
13	Towards Personalized Antioxidant Use in Female Infertility: Need for More Molecular and Clinical Studies. <i>Biomedicines</i> , 2021, 9, 1933.	1.4	9
14	Toward Molecular Medicine in Female Infertility Management: Editorial to the Special Issue "Molecular Mechanisms of Human Oogenesis and Early Embryogenesis". <i>International Journal of Molecular Sciences</i> , 2021, 22, 13517.	1.8	4
15	The value of virtual reality simulators in hysteroscopy and training capacity: a systematic review. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2020, 29, 185-193.	0.6	28
16	Vitamin D, reproductive disorders and assisted reproduction: evidences and perspectives. <i>International Journal of Food Sciences and Nutrition</i> , 2020, 71, 276-285.	1.3	29
17	Can miscarriage caused by delayed luteoplacental shift be avoided?. <i>Reproductive BioMedicine Online</i> , 2020, 41, 747.	1.1	4
18	The Effect of GH Administration on Oocyte and Zygote Quality in Young Women With Repeated Implantation Failure After IVF. <i>Frontiers in Endocrinology</i> , 2020, 11, 519572.	1.5	16

#	ARTICLE	IF	CITATIONS
19	Luteal Phase in Assisted Reproductive Technology. <i>Frontiers in Reproductive Health</i> , 2020, 2, .	0.6	8
20	Can the negative effects of vitrification on oocyte developmental competence be mitigated?. <i>Reproductive BioMedicine Online</i> , 2020, 41, 349.	1.1	1
21	After corona: there is life after the pandemic. <i>Reproductive BioMedicine Online</i> , 2020, 40, 760-762.	1.1	18
22	Melatonin attenuates growth factor receptor signaling required for SARS-CoV-2 replication. <i>Melatonin Research</i> , 2020, 3, 534-537.	0.7	10
23	Melatonin to Reduce Death Toll Due to COVID-19: From Innate to Adaptive Immune Response. <i>Global Journal of Medical Research</i> , 2020, , 5-7.	0.1	3
24	Patient-tailored luteal phase support with progesterone may avoid unnecessary oocyte donation failures. <i>Reproductive BioMedicine Online</i> , 2019, 39, 877.	1.1	0
25	GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study. <i>Reproductive BioMedicine Online</i> , 2019, 39, 225-230.	1.1	10
26	Effect of Growth Hormone on Uterine Receptivity in Women With Repeated Implantation Failure in an Oocyte Donation Program: A Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018, 2, 96-105.	0.1	58
27	Usefulness of individualized FSH, LH and GH dosing in ovarian stimulation of women with low ovarian reserve. <i>Human Reproduction</i> , 2018, 33, 981-982.	0.4	6
28	Is blastomere multinucleation a safeguard against embryo aneuploidy? Back to the future. <i>Reproductive BioMedicine Online</i> , 2018, 37, 506-507.	1.1	7
29	Melatonin: The First Noninvasive Causal Therapy for Both Endometriosis and Adenomyosis?. <i>Journal of Gynecology and Womens Health</i> , 2018, 12, .	0.1	6
30	Oocyte spindle transfer for prevention of mitochondrial disease: the question of membrane fusion technique. <i>Reproductive BioMedicine Online</i> , 2017, 35, 432.	1.1	3
31	Virtual ultrasonographic hysteroscopy followed by conventional operative hysteroscopy, enabling pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 188.e1.	0.7	10
32	Clinical scenarios of unexplained sperm DNA fragmentation and their management. <i>Translational Andrology and Urology</i> , 2017, 6, S566-S569.	0.6	11
33	Customized Assisted Reproduction Enhancement (CARE) for Women with Extremely Poor Ovarian Reserve (EPOR). <i>Journal of Gynecology and Womens Health</i> , 2017, 3, .	0.1	6
34	Gonadotropin-releasing hormone agonist for luteal phase support: the origin of the concept, current experience, mechanism of action and future perspectives. <i>Fertility and Sterility</i> , 2016, 106, 268-269.	0.5	8
35	High-magnification ICSI overcomes paternal effect resistant to conventional ICSI. <i>Reproductive BioMedicine Online</i> , 2006, 12, 19-25.	1.1	194
36	Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. <i>Human Reproduction</i> , 2006, 21, 2572-2579.	0.4	135

#	ARTICLE	IF	CITATIONS
37	Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Human Reproduction, 2005, 20, 2536-2541.	0.4	106
38	Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Human Reproduction, 2004, 19, 1176-1180.	0.4	111
39	Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Human Reproduction, 2002, 17, 3129-3137.	0.4	92
40	Day 3 embryo transfer with combined evaluation at the pronuclear and cleavage stages compares favourably with day 5 blastocyst transfer. Human Reproduction, 2002, 17, 1852-1855.	0.4	184
41	Paternal effects acting during the first cell cycle of human preimplantation development after ICSI. Human Reproduction, 2002, 17, 184-189.	0.4	181
42	Use of a modified intracytoplasmic sperm injection technique to overcome sperm-borne and oocyte-borne oocyte activation failures. Fertility and Sterility, 2002, 78, 619-624.	0.5	116
43	Sperm treatment with pentoxifylline improves the fertilizing ability in patients with acrosome reaction insufficiency. Fertility and Sterility, 1993, 60, 141-148.	0.5	59
44	Ultrastructural and autoradiographic observations on multinucleated blastomeres of human cleaving embryos obtained by in-vitro fertilization. Human Reproduction, 1987, 2, 127-136.	0.4	76
45	Patient-tailored reproductive health care. Frontiers in Reproductive Health, 0, 4, .	0.6	0